Latest news with #Gerresheimer
Reuters
16-07-2025
- Business
- Reuters
Gerresheimer calls a halt to discussions on potential takeover
July 16 (Reuters) - German packaging and medical equipment maker Gerresheimer ( opens new tab has ended discussions on a potential sale of the company, it said on Wednesday evening. In February the company had said it was in early discussions with private equity investors over a potential sale. "After a thorough analysis ... the company believes that continuing the discussions is not in the best interest of the company and its stakeholders," its statement said.
Business Insider
14-07-2025
- Business
- Business Insider
UBS Sticks to Its Buy Rating for Gerresheimer (0NTI)
In a report released today, Olivier Calvet from UBS maintained a Buy rating on Gerresheimer, with a price target of €75.00. The company's shares closed last Friday at €49.02. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Calvet covers the Industrials sector, focusing on stocks such as CTS Eventim AG & Co. KGaA, Gerresheimer, and Jenoptik. According to TipRanks, Calvet has an average return of 5.6% and a 51.56% success rate on recommended stocks. In addition to UBS, Gerresheimer also received a Buy from J.P. Morgan's David Adlington in a report issued on July 10. However, on July 11, Deutsche Bank maintained a Hold rating on Gerresheimer (LSE: 0NTI).
Reuters
10-07-2025
- Business
- Reuters
Gerresheimer cuts its 2025 revenue outlook for second time
July 10 (Reuters) - German packaging and medical equipment maker Gerresheimer ( opens new tab cut its revenue guidance for 2025 for a second time on Thursday, seeing continued weak demand in the cosmetic and oral liquids markets. It cut the lower end of its revenue growth forecast, now estimating a range of 0% to 2% growth in 2025, down from the previous range of 1-2%. "Growth momentum in the first half of the year overall was below our expectations," Dietmar Siemssen, CEO of Gerresheimer, said in a statement. While strong demand in drug delivery systems helped offset temporary market weakness for plastic containment solutions for oral liquids, boosting its plastics and devices business, its packaging glass business was hit by lower demand in moulded glass for cosmetics and in the market for oral liquids. The moulded glass business, which produces glass packaging for the food and beverage and cosmetic industry, is seen to be reducing growth, margins and returns, analysts at J.P. Morgan said in a research note. Following Gerresheimer's previous guidance cut in June, activist Asset Value Investor published an open letter in which it urged the company to take steps to improve its business. Those steps included potentially divesting its moulded glass business, a move supported by two other top 30 investors. Gerresheimer on Thursday confirmed its outlook for an adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) margin of around 20%, as it expects a stronger second half of the year. The medical packaging maker also cut its mid-term guidance, now expecting revenue growth in a range of 6-9%, down from a previous range of 8-10%, based on its outlook for 2025 and a stronger focus on cash flow, which led it to revise its investment planning.
Yahoo
10-07-2025
- Business
- Yahoo
Gerresheimer cuts its 2025 revenue outlook for second time
(Reuters) -German packaging and medical equipment maker Gerresheimer cut its revenue guidance for 2025 for a second time on Thursday, seeing continued weak demand in the cosmetic and oral liquids markets. It cut the lower end of its revenue growth forecast, now estimating a range of 0% to 2% growth in 2025, down from the previous range of 1-2%. "Growth momentum in the first half of the year overall was below our expectations," Dietmar Siemssen, CEO of Gerresheimer, said in a statement. However, it confirmed its outlook for an adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) margin of around 20%, as it expects a stronger second half of the year. The medical packaging maker also cut its mid-term guidance, now expecting revenue growth in a range of 6-9%, down from a previous range of 8-10%, based on its outlook for 2025 and a stronger focus on cash flow, which led it to revise its investment planning. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
18-06-2025
- Business
- Bloomberg
Stock Movers: Airbus, Gerresheimer, UBS
On this episode of Stock Movers: - Airbus shares rise as much as 2.3% after the planemaker said it was extending the upper range of its dividend payout ratio to 30-50% from the current level of 30-40%. - Gerresheimer said KPS Capital Partners is still in discussions with Warburg Pincus. Talks on a potential takeover 'are open-ended,' Gerresheimer said - UBS shares fell 1.7%, the worst performer in the Stoxx 600 Financial Services Index, after Morgan Stanley cut its recommendation on the Swiss lender to underweight from equalweight, saying that new capital demands imposed by Switzerland will impact shareholder returns.
